公开(公告)号：KR1020110037783A

公开(公告)日：2011-04-13

申请号：KR1020090095351

申请日：2009-10-07

Applicant: 전북대학교산학협력단 ,  전북대학교병원

Inventor： 이용철

IPC: A61K31/497 ,  A61P11/06

CPC classification number: A61K31/498 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/02 ,  A61K9/10 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  Y10S514/826

Abstract: PURPOSE: A pharmaceutical composition containing 5-(6-quinoxalinylmethylene)-2,4-thiazolidinedione(Cas No: 648450-29-7) is provided to prevent entrance of inflammatory cells into bronchial alveolar. CONSTITUTION: A pharmaceutical composition for treating and preventing bronchial asthma contains 5-(6-quinosalinylmethylene)-2,4-thiazolidinedione(Cas No: 648450-29-7). The composition is manufactured in the form of powder, granule, tablet, capsule, suspension, syrup, oral formulation of aerosol, suppository, or injection. The composition prevents or treats bronchial asthma by administering into mammal except for human. The composition is administered by airway injection.

Abstract translation: 目的：提供含有5-（6-喹喔啉亚甲基）-2,4-噻唑烷二酮（Cas No：648450-29-7）的药物组合物，以防止炎症细胞进入支气管肺泡。 构成：用于治疗和预防支气管哮喘的药物组合物含有5-（6-喹啉基亚甲基）-2,4-噻唑烷二酮（Cas No：648450-29-7）。 组合物以粉末，颗粒，片剂，胶囊，悬浮液，糖浆，气雾剂，栓剂或注射剂的口服制剂的形式制备。 该组合物通过给予哺乳动物除人之外预防或治疗支气管哮喘。 组合物通过气道注射给药。

公开(公告)号：KR1020080020039A

公开(公告)日：2008-03-05

申请号：KR1020060082814

申请日：2006-08-30

Applicant: 전북대학교산학협력단

Inventor： 이용철

IPC: A61K36/06 ,  A61P11/00

Abstract: A therapeutic agent of allergic airway disease and airway remodeling comprising wortmannin as a PI3K(phosphoinositide 3-kinases) inhibitor is provided to inhibit increased blood permeability and following inflammation responses and airway hypersensitiveness by suppressing VEGF(vascular endothelial growth factor). A 50-100mug of wortmannin as a PI3K(phosphoinositide 3-kinases) inhibitor is administered into the airway in 1-3 times at an interval of 48 hours to inhibit airway remodeling or VEGF, reduce vascular permeability or improve airway hypersensitiveness or airway inflammation in allergic airway disease. A therapeutic agent of allergic airway disease and airway remodeling comprises wortmannin as an effective ingredient.

Abstract translation: 提供包含渥曼青霉素作为PI3K（磷酸肌醇3-激酶）抑制剂的过敏性气道疾病和气道重塑的治疗剂，以通过抑制VEGF（血管内皮生长因子）来抑制增加的血液透过性和炎症反应和气道超敏感性。 以48小时间隔1-3次给予50-100MW作为PI3K（磷酸肌醇3-激酶）抑制剂的渥曼青霉素，以抑制气道重塑或VEGF，降低血管通透性或改善气道过敏或气道炎症 过敏性气道疾病 过敏性气道疾病和气道重塑的治疗剂包括渥曼青霉素作为有效成分。

公开(公告)号：KR1020080020013A

公开(公告)日：2008-03-05

申请号：KR1020060082701

申请日：2006-08-30

Applicant: 전북대학교산학협력단

Inventor： 이용철

IPC: A61K31/195 ,  A61P11/00

Abstract: A therapeutic agent of acute lung injury is provided to inhibit vascular endothelial growth factor(VEGF) and reduce increased VEGF and vascular permeability, so that it is useful for treating increased inflammation response and induced airway hyperresponsiveness. A therapeutic agent of acute lung injury comprises N-acetyl-L-cysteine which inhibits VEGF in the lung tissue, and reduces exudation of blood plasma in the lung tissue and vascular permeability as an effective ingredient, and is formulated as ample or vial, powder, granule, tablet, injection or suspension. The acute lung injury is treated by orally administering 2-5 mmol/kg, preferably 3 mmol/kg of N-acetyl-L-cysteine to a patient in 3-5 times at an interval of 24 hours.

Abstract translation: 提供急性肺损伤的治疗剂以抑制血管内皮生长因子（VEGF）并降低VEGF和血管渗透性增加，从而可用于治疗炎症反应增加和气道高反应性。 急性肺损伤的治疗剂包括抑制肺组织中的VEGF的N-乙酰基-L-半胱氨酸，并且减少肺组织中的血浆渗出和血管通透性作为有效成分，并且被配制为充足或小瓶，粉末 ，颗粒，片剂，注射剂或悬浮液。 通过以24小时间隔3-5次向患者口服2-5mmol / kg，优选3mmol / kg N-乙酰基-L-半胱氨酸治疗急性肺损伤。